Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Liposomal Bupivacaine Nerve Block for Knee Replacement Pain: Added Value and Optimization

Added Value and Optimization Strategies of Liposomal Bupivacaine Targeted Nerve Block in Multimodal Analgesia for Total Knee Arthroplasty: A Prospective, Randomized, Double-Blind, Three-Arm Controlled Clinical Trial

Background Total knee arthroplasty (TKA) effectively relieves end-stage knee osteoarthritis, yet moderate-to-severe postoperative pain substantially compromises early functional exercise and rehabilitation. Liposomal bupivacaine, with a duration of action of up to 72 hours, offers a means of extending the postoperative pain-free window. However, previous studies have been limited by non-standardized background analgesia, absent head-to-head comparison of block targets, reliance on short-term resting pain scores, and inadequate blinding. Consequently, both the added value of liposomal bupivacaine nerve block on top of intravenous patient-controlled analgesia (IV-PCA) plus local infiltration analgesia (LIA), and the optimal block target, remain unresolved.

Objective To determine the analgesic added value of a single-shot liposomal bupivacaine targeted nerve block superimposed on standardized multimodal analgesia, and to compare the analgesic and functional recovery profiles of alternative block targets, thereby informing an optimized perioperative analgesic strategy.

Methods In this prospective, randomized, double-blind, three-arm controlled trial, 〔n〕 patients scheduled for unilateral TKA will be randomized to 〔arms to be confirmed: (1) background analgesia alone; (2) adductor canal block (ACB); (3) ACB combined with IPACK block〕. All patients receive standardized background analgesia comprising IV-PCA and intraoperative LIA. The primary endpoint is movement-evoked pain numeric rating scale (NRS) score at 〔24〕 h postoperatively. Secondary endpoints include resting pain scores, cumulative opioid consumption, time to first ambulation, knee range of motion, incidence of postoperative nausea and vomiting (PONV), and length of hospital stay.

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Geschat)

210

Fase

  • Niet toepasbaar

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

65 jaar tot 85 jaar (Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:Age 65 to 85 years at the time of surgery. Scheduled for elective unilateral total knee arthroplasty for end-stage knee osteoarthritis.

Body mass index ≥18.5 and <25 kg/m². American Society of Anesthesiologists (ASA) physical status I to III. Written informed consent obtained from the patient before any study procedure. Able to understand and use the numeric rating scale (NRS) for pain and to complete the quality-of-recovery questionnaire.

Exclusion Criteria:Refusal to participate, or withdrawal of consent at any time.

Known allergy or hypersensitivity to bupivacaine, ropivacaine, oxycodone, or other study-related medications.

Infection at or near the planned puncture sites, or systemic infection. Coagulopathy, or current anticoagulant/antiplatelet therapy that precludes deep peripheral nerve block.

Pre-existing peripheral neuropathy, motor or sensory deficit in the operated limb, or other contraindication to neuraxial/peripheral block.

Chronic opioid use (≥3 months) or a history of opioid dependence. Severe hepatic or renal impairment (e.g. eGFR <30 mL/min/1.73 m², or Child-Pugh class B/C).

Severe cardiopulmonary disease (e.g. unstable angina, NYHA class III-IV heart failure, severe COPD), or ASA physical status IV or higher.

Preoperative knee flexion contracture >15° or varus deformity >15°, or previous surgery on the index knee (including prior arthroplasty).

Cognitive impairment, psychiatric disorder, illiteracy, or language barrier that would prevent valid pain and recovery assessment.

Participation in another interventional trial within 30 days. Vulnerable populations: minors, pregnant or lactating women, prisoners, and persons unable to give voluntary informed consent.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Dubbele

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Adductor Canal Block (ACB)

Liposomal bupivacaine is a multivesicular liposomal formulation of bupivacaine that provides prolonged release of the local anesthetic from the injection site. In this trial it is administered as a single injection under ultrasound guidance, at a dose of 〔133 mg/10 mL〕 for the adductor canal block and 〔133 mg/10 mL〕 for the IPACK block, with the total dose per patient not exceeding 266 mg. The preparation is used in accordance with the manufacturer's instructions and is not admixed with other local anesthetics.

A single-shot adductor canal block is performed by an anesthesiologist experienced in regional anesthesia, after induction of anesthesia and before surgical incision. With the patient supine and the operative limb abducted and externally rotated, a high-frequency linear transducer is placed on the medial mid-thigh at the level between the anterior superior iliac spine and the patella. Under real-time in-plane guidance, a 22-gauge needle is advanced from lateral to medial until the tip lies deep to the sartorius muscle, adjacent to the superficial femoral artery within the adductor canal. After negative aspiration, the study solution is injected with intermittent aspiration, and circumferential spread around the artery is confirmed by hydrodissection.

Experimenteel: ACB Plus IPACK Block

Liposomal bupivacaine is a multivesicular liposomal formulation of bupivacaine that provides prolonged release of the local anesthetic from the injection site. In this trial it is administered as a single injection under ultrasound guidance, at a dose of 〔133 mg/10 mL〕 for the adductor canal block and 〔133 mg/10 mL〕 for the IPACK block, with the total dose per patient not exceeding 266 mg. The preparation is used in accordance with the manufacturer's instructions and is not admixed with other local anesthetics.

A single-shot adductor canal block is performed by an anesthesiologist experienced in regional anesthesia, after induction of anesthesia and before surgical incision. With the patient supine and the operative limb abducted and externally rotated, a high-frequency linear transducer is placed on the medial mid-thigh at the level between the anterior superior iliac spine and the patella. Under real-time in-plane guidance, a 22-gauge needle is advanced from lateral to medial until the tip lies deep to the sartorius muscle, adjacent to the superficial femoral artery within the adductor canal. After negative aspiration, the study solution is injected with intermittent aspiration, and circumferential spread around the artery is confirmed by hydrodissection.

A single-shot IPACK (interspace between the popliteal artery and the capsule of the posterior knee) block is performed with the patient supine and the knee flexed approximately 30 degrees. A high-frequency linear transducer is positioned in the popliteal crease with the popliteal artery identified in short axis, and a 22-gauge needle is advanced in-plane from medial to lateral until the tip lies in the fascial plane between the popliteal artery and the posterior capsule of the knee. After negative aspiration, the study solution is injected with real-time visualization of spread along this plane, without puncturing the popliteal vessels.

Geen tussenkomst: Background Analgesia Alone

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Proportion of Patients Achieving Pain-Free Rehabilitation Within 72 Hours After Surgery (Composite)
Tijdsspanne: 72 hours after surgery

Composite primary endpoint, defined as the proportion of patients meeting all three of the following criteria within 72 hours after surgery: (1) adequate pain control-numeric rating scale (NRS) score ≤3 for movement-evoked pain during 45° knee flexion at 24, 48, and 72 hours postoperatively; (2) functional progress-ability to walk ≥20 m with assistance within 72 hours; and (3) opioid sparing-cumulative intravenous oxycodone consumption ≤40 mg (or morphine-equivalent dose) from 0 to 72 hours postoperatively.

72 hours after surgery

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 december 2026

Primaire voltooiing (Geschat)

1 december 2028

Studie voltooiing (Geschat)

1 december 2028

Studieregistratiedata

Eerst ingediend

10 november 2026

Eerst ingediend dat voldeed aan de QC-criteria

10 november 2026

Eerst geplaatst (Werkelijk)

16 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

16 november 2026

Laatste update ingediend die voldeed aan QC-criteria

10 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

ONBESLIST

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren